Butyrylcholinesterase in lipid metabolism: A new outlook
- PMID: 37129444
- DOI: 10.1111/jnc.15833
Butyrylcholinesterase in lipid metabolism: A new outlook
Abstract
Cholinesterase enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are traditionally associated with the termination of acetylcholine mediated neural signaling. The fact that these ubiquitous enzymes are also found in tissues not involved in neurotransmission has led to search for alternative functions for these enzymes. Cholinesterases are reported to be involved in many lipid related disease states. Taking into view that lipases and cholinesterases belong to the same enzyme class and by comparing the catalytic sites, we propose a new outlook on the link between BChE and lipid metabolism. The lipogenic substrates of BChE that have recently emerged in contrast to traditional cholinesterase substrates are explained through the hydrolytic capacity of BChE for ghrelin, 4-methyumbelliferyl (4-mu) palmitate, and arachidonoylcholine and through endogenous lipid mediators such as cannabinoids like anandamide and essential fatty acids. The abundance of BChE in brain, intestine, liver, and plasma, tissues with active lipid metabolism, supports the idea that BChE may be involved in lipid hydrolysis. BChE is also regulated by various lipids such as linoleic acid, alpha-linolenic acid or dioctanoylglycerol, whereas AChE is inhibited. The finding that BChE is able to hydrolyze 4-mu palmitate at a pH where lipases are less efficient points to its role as a backup in lipolysis. In diseases such as Alzheimer, in which elevated BChE and impaired lipid levels are observed, the lipolytic activity of BChE might be involved. It is possible to suggest that fatty acids such as 4-mu palmitate, ghrelin, arachidonoylcholine, essential fatty acids, and other related lipid mediators regulate cholinesterases, which could lead to some sort of compensatory mechanism at high lipid concentrations.
Keywords: butyrylcholinesterase; endogenous lipid modulators; essential fatty acids; lipid hydrolysis; lipid metabolism; palmitate.
© 2023 International Society for Neurochemistry.
References
REFERENCES
-
- Akay, M. B., Sener, K., Sari, S., & Bodur, E. (2022). Inhibitory action of omega‐3 and omega‐6 fatty acids alpha‐Linolenic, arachidonic and linoleic acid on human erythrocyte acetylcholinesterase. The Protein Journal, 1‐8, 96–103. https://doi.org/10.1007/s10930‐022‐10088‐z
-
- Akimov, M. G., Kudryavtsev, D. S., Kryukova, E. V., Fomina‐Ageeva, E. V., Zakharov, S. S., Gretskaya, N. M., Zinchenko, G. N., Serkov, I. V., Makhaeva, G. F., Boltneva, N. P., Kovaleva, N. V., Serebryakova, O. G., Lushchekina, S. V., Palikov, V. A., Palikova, Y., Dyachenko, I. A., Kasheverov, I. E., Tsetlin, V. I., & Bezuglov, V. V. (2020). Arachidonoylcholine and other unsaturated long‐chain Acylcholines are endogenous modulators of the acetylcholine signaling system. Biomolecules, 10(2), 283. https://doi.org/10.3390/biom10020283
-
- Alcantara, V. M., Chautard‐Freire‐Maia, E. A., Scartezini, M., Cerci, M. S., Braun‐Prado, K., & Picheth, G. (2002). Butyrylcholinesterase activity and risk factors for coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation, 62(5), 399–404. https://doi.org/10.1080/00365510260296564
-
- Ballard, C. (2002). Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition. European Neurology, 47(1), 64–70.
-
- Bodur, E., & Layer, P. G. (2014). PKC stimulation increases expression of cholinesterases in R28 cell line. Turkish Journal of Biochemistry‐Turk Biyokimya Dergisi, 39(2), 201–205. https://doi.org/10.5505/tjb.2014.38981
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
